Biomarkers play an essential role in the management of patients with invasive breast
cancer. For selecting patients likely to respond to endocrine therapy, both oestrogen …

Breast cancer is the most common type of cancer found in women and today represents a
significant challenge to public health. With the latest breakthroughs in molecular biology and …

Importance ERRB2 (formerly HER2)–positive advanced breast cancer (ABC) remains
typically incurable with optimal treatment undefined in later lines of therapy. The chimeric …

PURPOSE To update evidence-based guideline recommendations to practicing oncologists
and others on systemic therapy for patients with human epidermal growth factor receptor 2 …

Purpose.—To update key recommendations of the American Society of Clinical Oncology
(ASCO)/College of American Pathologists (CAP) human epidermal growth factor receptor 2 …

Background Trastuzumab deruxtecan (DS-8201a) is a novel HER2-targeted antibody–drug
conjugate with a humanised anti-HER2 antibody, cleavable peptide-based linker, and …

Background Antibody–drug conjugates have emerged as a powerful strategy in cancer
therapy and combine the ability of monoclonal antibodies to specifically target tumour cells …

Importance Given recent advances in screening mammography and adjuvant therapy
(treatment), quantifying their separate and combined effects on US breast cancer mortality …

The analysis of cell-free DNA (cfDNA) in plasma represents a rapidly advancing field in
medicine. cfDNA consists predominantly of nucleosome-protected DNA shed into the …

Purpose To provide recommendations on the appropriate use of breast tumor biomarker
assay results to guide decisions on systemic therapy for metastatic breast cancer. Methods A …